1
|
Nirwan JS, Farhaj S, Chaudhary MM, Khizer Z, Hasan SS, Angelis-Dimakis A, Gill A, Rasheed H, Abbas N, Arshad MS, Hussain T, Shahzad Y, Yousaf AM, Chohan TA, Hussain T, Merchant HA, Akram MR, Khan TM, Ashraf M, Conway BR, Ghori MU. Exploration of a New Source of Sustainable Nanomaterial from the Koh-e-Suleiman Mountain Range of Pakistan for Industrial Applications. Sci Rep 2020; 10:577. [PMID: 31953500 PMCID: PMC6969096 DOI: 10.1038/s41598-020-57511-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Accepted: 12/27/2019] [Indexed: 11/29/2022] Open
Abstract
The present study aimed to explore a new source of montmorillonite and to develop an extraction and purification protocol for its isolation from raw clay samples acquired from the Koh-e-Suleiman mountain range in Pakistan. The process involved the collection of raw clay from the source, identification and quantification of montmorillonite. Granulometric extraction and purification protocols increased the montmorillonite content from 21.8-25.1% in the raw clay to 90.1-93.9% after small-scale extraction and 85.33-89.33% on a larger scale. A techno-economic analysis highlighted the practicality and economic benefits of large-scale extraction for industrial applications. This study highlights the existence of a substantial new source of this valuable clay which is currently used across multiple industries including construction, pottery making, pharmaceuticals, cosmetics and engineering. It is intuitively expected that the large-scale extraction of the material will improve the economic condition of the region by providing employment opportunities to locals and may be a valuable resource for export.
Collapse
Affiliation(s)
- J S Nirwan
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK
| | - S Farhaj
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK
| | | | - Z Khizer
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK
| | - S S Hasan
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK
| | - A Angelis-Dimakis
- Department of Chemical Sciences, University of Huddersfield, Huddersfield, UK
| | - A Gill
- Ministry of Minerals and Mines, Lahore, Punjab, Pakistan
| | - H Rasheed
- Pakistan Council of research for Water Resources (PCRWR), Ministry of Science and Technology, Islamabad, Pakistan
| | - N Abbas
- University College of Pharmacy, the University of Punjab, Lahore, Pakistan
| | - M S Arshad
- Faculty of Pharmacy, Bahuddin Zakariya University Multan, Multan, Pakistan
| | - T Hussain
- Department of Pharmacy, COMSAT University Islamabad, Lahore Campus, Lahore, Pakistan
| | - Y Shahzad
- Department of Pharmacy, COMSAT University Islamabad, Lahore Campus, Lahore, Pakistan
| | - A M Yousaf
- Department of Pharmacy, COMSAT University Islamabad, Lahore Campus, Lahore, Pakistan
| | - T A Chohan
- Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan
| | - T Hussain
- The Wolfson Centre for Bulk Solid Handling Technology, University of Greenwich, London, UK
- System Engineering Department, Military Technological College, Muscat, Oman
| | - H A Merchant
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK
| | - M R Akram
- College of Pharmacy, University of Sargodha, Sargodha, 40100, Pakistan
| | - T M Khan
- Institute of Pharmaceutical Sciences, University of Veterinary and Animal Sciences, Lahore, Pakistan
| | - M Ashraf
- Pakistan Council of research for Water Resources (PCRWR), Ministry of Science and Technology, Islamabad, Pakistan
| | - B R Conway
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK
| | - M U Ghori
- Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield, HD1 3DH, UK.
| |
Collapse
|
2
|
Azhar S, Hassali MA, Igbal A, Akram MR, Attique-Ur-Rehman M, Karim S, Tariq I, Asad MHHB, Tarjik I, Murtaza G. Qualitative Assessment of the Pharmacist’s Role in Punjab, Pakistan: Medical Practitioners’ Views. TROP J PHARM RES 2015. [DOI: 10.4314/tjpr.v14i2.19] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
4
|
Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, Coghlan JG. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006; 92:926-32. [PMID: 16339813 PMCID: PMC1860719 DOI: 10.1136/hrt.2005.069484] [Citation(s) in RCA: 183] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 11/09/2005] [Indexed: 12/24/2022] Open
Abstract
OBJECTIVES To measure survival, haemodynamic function and functional class in patients with systemic sclerosis associated pulmonary arterial hypertension (SSc-PAH) in two treatment eras. METHODS Six year longitudinal study of 92 consecutive patients with SSc-PAH diagnosed by cardiac catheterisation. Data were collected both prospectively and retrospectively. Patients were given basic treatment (diuretics, digoxin, oxygen and warfarin). Where clinically indicated, a prostanoid was used as advanced treatment (historical control group). From 2002, the range of treatments available expanded to include bosentan, which was generally the preferred treatment (current treatment era group). Survival was measured from the date of diagnosis of pulmonary hypertension by cardiac catheterisation. Six minute walking distance and haemodynamic function were measured at the time of diagnosis and at least one month after treatment was started. RESULTS The historical control group comprised 47 patients, all of whom received basic treatment; 27 of these were also treated with prostanoids. The current treatment era group comprised 45 patients, all of whom received bosentan as preferred treatment. Kaplan-Meier survival in the historical control group was 68% at one year and 47% at two years. Survival in the current treatment era group was 81% and 71% (p = 0.016) at one and two years, respectively. Pulmonary vascular resistance increased in the historical control group (by 147 dyn.s.cm(-5)), whereas in the current treatment era group, it remained stable over an average of nine months (decrease of 16 dyn x s x cm(-5), p < 0.006). CONCLUSION Survival of selected patients with SSc-PAH has improved in the current treatment era. In contrast to patients treated historically with basic drugs and prostanoids, patients treated in the current treatment era had improved survival associated with a lack of deterioration in cardiac haemodynamic function.
Collapse
Affiliation(s)
- M H Williams
- Department of Cardiology, Royal Free Hospital, London, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Akram MR, Handler CE, Williams M, Carulli MT, Andron M, Black CM, Denton CP, Coghlan JG. Angiographically proven coronary artery disease in scleroderma. Rheumatology (Oxford) 2006; 45:1395-8. [PMID: 16606654 DOI: 10.1093/rheumatology/kel120] [Citation(s) in RCA: 66] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
OBJECTIVE It has been suggested that macrovascular disease is more common in patients with scleroderma (SSc). We investigated the prevalence of coronary artery disease (CAD) in SSc using coronary angiography. METHODS Coronary angiography was performed in 172 patients with SSc and suspected CAD to examine the prevalence of significant CAD. The prevalence of CAD was estimated in the whole group and also according to age, gender and type of symptoms (typical angina, atypical angina and non-anginal pain or breathlessness). Standardized prevalence ratios (SPRs) were calculated in each symptomatic group in order to compare CAD rates amongst our observed population with those predicted using the Diamond and Forrester (D & F) probability analysis. This analysis provides an estimate of the probability of CAD based on gender, age and symptoms in subjects aged between 30-69 yrs. RESULTS The observed prevalence of CAD in the whole population was 22% (38/172); 17% (6/36) in males and 23% (32/136) in females. A total of 41 patients were excluded because they were outside the age range for D & F analysis. Compared with the reference population, the SPRs for CAD in the three SSc groups were: 47% (95% CI 21.7-89.9) in the typical angina group (22 patients), 50% (95% CI 13.6-128) in the atypical angina group (22 patients) and 93% (95% CI 49.4-158.8) in the non-anginal pain or breathlessness group (87 patients). CONCLUSION The prevalence of CAD in patients with SSc is similar and not greater to that expected in individuals without SSc.
Collapse
Affiliation(s)
- M R Akram
- Department of Cardiology, Royal Free Hospital, London, NW3 2QG, UK
| | | | | | | | | | | | | | | |
Collapse
|